The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
|Articles|September 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Epilepsy and Its Medical Management
- Volume 4
- Issue 9 Suppl
CME Quiz
Advertisement
Articles in this issue
about 28 years ago
Participating Facultyabout 28 years ago
Medical Management of Epilepsy: Issues and Implicationsabout 28 years ago
Demographics and Cost of Epilepsyabout 28 years ago
Anticonvulsants: Choices and Costsabout 28 years ago
Care of Children With Epilepsyabout 28 years ago
Referral Centers and Specialized Careabout 28 years ago
Vagus Nerve Stimulationabout 28 years ago
Determining Costs and Cost-Effectiveness of Epilepsyabout 28 years ago
Selected Abstractsabout 28 years ago
BibliographyAdvertisement
Related to this article
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Cleveland roundtable panelists across 4 disease states name access, not evidence, as the shared barrier to care.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.
Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.
Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.
Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5